2020 Executive Sponsors

Adaptive Biotech

2020 Associate Sponsor

PRA Health Sciences

2020 Educational & Supporting Partners

California Life Sciences Association (CLSA)
Cancer Research Institute CRI
Society for Immunotherapy of Cancer (SITC)

2020 Media Partners

Life Science Leader


The Latest Data Impacting Immuno-Oncology Combinations and Patient Treatment
Perspectives Representing Science, Clinical and Business

The 5th annual IO Combinations 360°  is dedicated to fulfilling its mission to address clinical developments, scientific data and business aspects in IO combination strategies. The rapid advancement in our understanding of human cancer immunity and immunotherapy combinations is nearly impossible for individual scientists to comprehend. Only together, as an engaged and interactive scientific community, can we hope to enable a patient’s immune system to eradicate cancer.

IO Combinations 360° Delivers Three Key Benefits:

  1. Access to KOLs driving the science
  2. Partnership opportunities with all stakeholders in Immuno-Oncology & Combinations
  3. Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology Combinations


2020 Strategic Leadership

Featured Speakers



Key Topic Areas for 2020

  • Discovery / Preclinical Science
  • Bispecifics
  • Translational Science & Biomarkers
  • Next Generation Cell Therapy
  • Clinical Developments
  • Operationalizing Combinations
  • Business Aspects
  • Emerging Technologies




Kate Woda
Conference Director

Valerie Bowling New

Valerie Bowling
Executive Director


Meredith Sands
Executive Director, Business Development

Elizabeth Bard B&W-47

Elizabeth Bard
Business Development Manager

Adam Kolanko
Business Development Manager


Meg Gould
Senior Conference Planner


Bre Bugbee
Marketing Manager




  • "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

    - Roy Baynes, Merck Research Labs

  • "I absolutely enjoyed the meeting! It was great getting both academia and industry together to discuss how we move forward."

    - Robert Andtbacka, Huntsman Cancer Institute

  • "Thanks so much for putting on a great conference. It was very informative and I was excited to be a part of it. I am looking forward to the next one!"

    - Amanda Bruno, GSK

  • "It was a great conference. I learned a lot and enjoyed the diversity of speakers"

    - Julia Keith, RA Capital

  • "It was great meeting. I really enjoyed the conference and my interactions with several of the participants."

    - Jeffrey Wallin, Genentech